Effects of dipeptidyl peptidase-4 (DPP-4) inhibitor, alogliptin, on coronary atherosclerosis in patients with type 2 diabetes mellitus
Phase of Trial: Phase IV
Latest Information Update: 22 Oct 2018
Price : $35 *
At a glance
- Drugs Alogliptin (Primary)
- Indications Coronary arteriosclerosis; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 15 Oct 2018 Status changed from active, no longer recruiting to completed.
- 10 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Oct 2014 New trial record